References
1. Chibber P, Haq SA, Ahmed
I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19:
A review. European journal of pharmacology. 2020 Jul 16:173372.
2. Zhang XY, Huang HJ,
Zhuang DL, Nasser MI, Yang MH, Zhu P, et al. Biological, clinical and
epidemiological features of COVID-19, SARS and MERS and AutoDock
simulation of ACE2. Infectious diseases of poverty. 2020 Jul 20;9(1):99.
3. Cui N, Zou X, Xu L.
Preliminary CT findings of coronavirus disease 2019 (COVID-19). Clinical
imaging. 2020 Sep;65:124-32.
4. Huang C, Wang Y, Li X,
Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020
Feb 15;395(10223):497-506.
5. Jamwal S, Gautam A,
Elsworth J, Kumar M, Chawla R, Kumar P. An updated insight into the
molecular pathogenesis, secondary complications and potential
therapeutics of COVID-19 pandemic. Life sciences. 2020 Jul
17;257:118105.
6. Arachchillage DRJ, Laffan
M. Abnormal coagulation parameters are associated with poor prognosis in
patients with novel coronavirus pneumonia. Journal of thrombosis and
haemostasis : JTH. 2020 May;18(5):1233-4.
7. Tang N, Bai H, Chen X,
Gong J, Li D, Sun Z. Anticoagulant treatment is associated with
decreased mortality in severe coronavirus disease 2019 patients with
coagulopathy. Journal of thrombosis and haemostasis : JTH. 2020
May;18(5):1094-9.
8. Chen ZR, Zhou Y, Liu J,
Peng HW, Zhou J, Zhong HL, et al. Pharmacotherapics Advice in Guidelines
for COVID-19. Frontiers in pharmacology. 2020;11:950.
9. AIFA. Farmaci
utilizzabili per il trattamento della malattia COVID-19. Available
on-line:
https://wwwaifagovit/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19
Last accessed: 04 August 2020. 2020.
10. Rossotti R, Travi G,
Ughi N, Corradin M, Baiguera C, Fumagalli R, et al. Safety and efficacy
of anti-il6-receptor tocilizumab use in severe and critical patients
affected by coronavirus disease 2019: A comparative analysis. The
Journal of infection. 2020 Jul 8.
11. Vinetz JM. Lack of
efficacy of hydroxychloroquine in covid-19. BMJ (Clinical research ed).
2020 May 19;369:m2018.
12. AIFA. Idrossiclorochina
nella terapia dei pazienti adulti con COVID-19. Available on-line:
https://wwwaifagovit/documents/20142/1123276/idrossiclorochina_22072020pdf/764add8f-f08f-0e26-df75-952986e54b8b
Last accessed: 04 August 2020. 2020.
13. AIFA.
Darunavir/cobicistat nella terapia dei pazienti adulti con COVID-19.
Available on-line:
https://wwwaifagovit/documents/20142/1123276/darunavir_cobicistat_17072020pdf/6e34d1cf-9d14-4e01-8229-6467de2da082
Last accessed: 04 August 2020. 2020.
14. AIFA.
Lopinavir/ritonavir nella terapia dei pazienti adulti con COVID-19.
Available on-line:
https://wwwaifagovit/documents/20142/1123276/lopinavir_ritonavir_17072020pdf/ab9e07d8-585b-6eda-0007-a8f3d1e175c4
Last accessed: 04 August 2020. 2020.
15. Sun J, Deng X, Chen X,
Huang J, Huang S, Li Y, et al. Incidence of Adverse Drug Reactions in
COVID-19 Patients in China: An Active Monitoring Study by Hospital
Pharmacovigilance System. Clinical pharmacology and therapeutics. 2020
Apr 23.
16. Tuccori M, Convertino I,
Ferraro S, Cappello E, Valdiserra G, Focosi D, et al. The Impact of the
COVID-19 ”Infodemic” on Drug-Utilization Behaviors: Implications for
Pharmacovigilance. Drug Saf. 2020 Aug;43(8):699-709.
17. Mazzitello C, Esposito
S, De Francesco AE, Capuano A, Russo E, De Sarro G. Pharmacovigilance in
Italy: An overview. Journal of pharmacology & pharmacotherapeutics.
2013 Dec;4(Suppl 1):S20-8.
18. Lombardi N, Crescioli G,
Bettiol A, Marconi E, Vitiello A, Bonaiuti R, et al. Characterization of
serious adverse drug reactions as cause of emergency department visit in
children: a 5-years active pharmacovigilance study. BMC pharmacology &
toxicology. 2018 Apr 16;19(1):16.
19. Lombardi N, Crescioli G,
Bettiol A, Tuccori M, Rossi M, Bonaiuti R, et al. Vaccines Safety in
Children and in General Population: A Pharmacovigilance Study on Adverse
Events Following Anti-Infective Vaccination in Italy. Frontiers in
pharmacology. 2019;10:948.
20. Naranjo CA, Busto U,
Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating
the probability of adverse drug reactions. Clinical pharmacology and
therapeutics. 1981 Aug;30(2):239-45.
21. Drugs.com. Drug
Interactions Checker. Available on-line:
https://wwwdrugscom/interaction/list/?drug_list= Last accessed: 04
August 2020.
22. 2.0 M. Drug
Interactions. Available on-line:
https://wwwmicromedexsolutionscom/micromedex2/4340/WebHelp/Tools/Interactions/Drug_Interactions_severity_definitionshtm
Last accessed: 04 August 2020. 2013.
23. Lombardi N, Bettiol A,
Crescioli G, Ravaldi C, Bonaiuti R, Venegoni M, et al. Risk of
hospitalisation associated with benzodiazepines and z-drugs in Italy: a
nationwide multicentre study in emergency departments. Internal and
emergency medicine. 2020 Apr 24.
24. Lombardi N, Crescioli G,
Bettiol A, Tuccori M, Capuano A, Bonaiuti R, et al. Italian Emergency
Department Visits and Hospitalizations for Outpatients’ Adverse Drug
Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS
Study). Frontiers in pharmacology. 2020;11:412.
25. Hult S, Sartori D,
Bergvall T, Hedfors Vidlin S, Grundmark B, Ellenius J, et al. A
Feasibility Study of Drug-Drug Interaction Signal Detection in Regular
Pharmacovigilance. Drug Saf. 2020 Aug;43(8):775-85.
26. Laurence L. Brunton BAC,
Bjorn C. Knollman. Quinolines and related compounds. In: Brunton LL,
editor. Goodman and Gilman’s The Pharmacological Basis of Therapeutics,
Twelfth Edition 12th Edition. New York: McGraw-Hill Companies; 2011. p.
Chapter 49; pages 1270-2.
27. Venisse N. Potential
drug-drug interactions associated with drugs currently proposed for
COVID-19 treatment in patients receiving other treatments. Fundamental
& clinical pharmacology. 2020 Jul 2.
28. Kelly M, O’Connor R,
Townsend L, Coghlan M, Relihan E, Moriarty M, et al. Clinical outcomes
and adverse events in patients hospitalised with COVID-19, treated with
off-label hydroxychloroquine and azithromycin. British journal of
clinical pharmacology. 2020 Jul 20.
29. Lu ZK, Yuan J, Li M,
Sutton SS, Rao GA, Jacob S, et al. Cardiac risks associated with
antibiotics: azithromycin and levofloxacin. Expert opinion on drug
safety. 2015 Feb;14(2):295-303.
30. EMA. Kaletra - Annex I -
Summary of product characteristics. Available on-line:
https://wwwemaeuropaeu/en/documents/product-information/kaletra-epar-product-information_enpdf
Last accessed: 04 August 2020.
31. EMA. Prezista - Annex I
- Summary of product characteristics. Available on-line:
https://wwwemaeuropaeu/en/documents/product-information/prezista-epar-product-information_enpdf
Last accessed: 04 August 2020.
32. Kallergis EM, Goudis CA,
Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors,
and management of acquired long QT syndrome: a comprehensive review.
TheScientificWorldJournal. 2012;2012:212178.
33. Rajkumar RP. COVID-19
and mental health: A review of the existing literature. Asian journal of
psychiatry. 2020 Apr 10;52:102066.
34. Tandon R. The COVID-19
pandemic, personal reflections on editorial responsibility. Asian
journal of psychiatry. 2020 Apr;50:102100.
35. Rogers JP, Chesney E,
Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and
neuropsychiatric presentations associated with severe coronavirus
infections: a systematic review and meta-analysis with comparison to the
COVID-19 pandemic. The lancet Psychiatry. 2020 Jul;7(7):611-27.
36. AIFA. Zitromax -
Riassunto delle caratteristiche del prodotto. Available on-line:
https://farmaciagenziafarmacogovit/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000040_027860_RCPpdf&retry=0&sys=m0b1l3
Last accessed: 04 August 2020.
37. EMA. Relzosta - Annex I
- Summary of product characteristics. Available on-line:
https://wwwemaeuropaeu/en/documents/product-information/rezolsta-epar-product-information_enpdf
Last accessed: 04 August 2020.
38. EMA. Roactemra - Annex I
- Summary of product characteristics. Available on-line:
https://wwwemaeuropaeu/en/documents/product-information/roactemra-epar-product-information_enpdf
Last accessed: 04 August 2020.
39. Das EM, Mohan D.
Chloroquine-related depression. Indian J Psychiatry. 1981
Apr;23(2):184-5.
40. Lovestone S.
Chloroquine-induced mania. The British journal of psychiatry : the
journal of mental science. 1991 Jul;159:164-5.
41. Bogaczewicz A, Sobow T,
Bogaczewicz J, Bienkowski P, Kowalski J, Wozniacka A.
Chloroquine-induced subacute paranoid-like disorder as a complication of
dermatological treatment. International journal of dermatology. 2016
Dec;55(12):1378-80.
42. Bogaczewicz J, Sobow T,
Bogaczewicz A, Robak E, Bienkowski P, Sysa-Jedrzejowska A, et al.
Exacerbations of bipolar disorder triggered by chloroquine in systemic
lupus erythematosus–a case report. Lupus. 2014 Feb;23(2):188-93.
43. Emmanuel S, Ostlundh L.
Psychiatric adverse events with hydroxychloroquine during COVID-19
pandemic. Asian journal of psychiatry. 2020 Jun 20;54:102203.
44. Bitta MA, Kariuki SM,
Mwita C, Gwer S, Mwai L, Newton C. Antimalarial drugs and the prevalence
of mental and neurological manifestations: A systematic review and
meta-analysis. Wellcome open research. 2017;2:13.
45. Sato K, Mano T, Iwata A,
Toda T. Neuropsychiatric adverse events of chloroquine: a real-world
pharmacovigilance study using the FDA Adverse Event Reporting System
(FAERS) database. Bioscience trends. 2020 May 21;14(2):139-43.
46. Mascolo A, Berrino PM,
Gareri P, Castagna A, Capuano A, Manzo C, et al. Neuropsychiatric
clinical manifestations in elderly patients treated with
hydroxychloroquine: a review article. Inflammopharmacology. 2018
Oct;26(5):1141-9.
47. Turjanski N. LGG.
Psychiatric side-effects of medications: recent developments. Advances
in Psychiatric Treatment. 2005;11:58-70.
48. Winston A, Fatkenheuer
G, Arribas J, Hill A, van Delft Y, Moecklinghoff C. Neuropsychiatric
adverse events with ritonavir-boosted darunavir monotherapy in
HIV-infected individuals: a randomised prospective study. HIV clinical
trials. 2010 May-Jun;11(3):163-9.
49. Pfefferbaum B, North CS.
Mental Health and the Covid-19 Pandemic. The New England journal of
medicine. 2020 Aug 6;383(6):510-2.
50. Ravaldi C, Wilson A,
Ricca V, Homer C, Vannacci A. Pregnant women voice their concerns and
birth expectations during the COVID-19 pandemic in Italy. Women and
birth : journal of the Australian College of Midwives. 2020 Jul 13.
51. Matvienko-Sikar K,
Meedya S, Ravaldi C. Perinatal mental health during the COVID-19
pandemic. Women and birth : journal of the Australian College of
Midwives. 2020 Jul;33(4):309-10.
52. FDA. PLAQUENIL®
HYDROXYCHLOROQUINE SULFATE, USP. Available on-line:
https://wwwaccessdatafdagov/drugsatfda_docs/label/2007/009768s041lblpdf
Last accessed: 04 Agust 2020.
53. Lin L, Jiang X, Zhang Z,
Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases
with SARS-CoV-2 infection. Gut. 2020 Jun;69(6):997-1001.
Table 1. Indication of use and mechanism of action of principal
SARS-CoV-2 medications in Italy.